GCP
IMVT icon

GSA Capital Partners’s Immunovant IMVT Stock Holding History

GSA Capital Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.52M Sell
65,267
-7,553
-10% -$230K 0.16% 93
2026
Q1 		$1.81M Buy
72,820
+28,680
+65% +$743K 0.11% 196
2025
Q4 		$1.12M Buy
44,140
+16,992
+63% +$379K 0.1% 302
2025
Q3 		$438K Buy
+27,148
New +$440K 0.04% 941
2024
Q4 		– Sell
-24,634
Closed -$702K – 1795
2024
Q3 		$702K Buy
24,634
+9,810
+66% +$289K 0.05% 686
2024
Q2 		$391K Buy
+14,824
New +$422K 0.03% 1122
2024
Q1 		– Sell
-8,760
Closed -$369K – 1788
2023
Q4 		$369K Buy
+8,760
New +$322K 0.03% 1000
2023
Q3 		– Sell
-32,736
Closed -$621K – 1687
2023
Q2 		$621K Buy
+32,736
New +$610K 0.06% 606
2022
Q4 		– Sell
-95,146
Closed -$531K – 1655
2022
Q3 		$531K Buy
95,146
+55,329
+139% +$270K 0.07% 523
2022
Q2 		$155K Buy
+39,817
New +$172K 0.02% 1132
2022
Q1 		– Sell
-40,654
Closed -$346K – 1597
2021
Q4 		$346K Sell
40,654
-40,516
-50% -$334K 0.04% 845
2021
Q3 		$705K Buy
+81,170
New +$732K 0.07% 494
2021
Q1 		– Sell
-5,175
Closed -$239K – 1280
2020
Q4 		$239K Buy
+5,175
New +$239K 0.04% 877

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GSA Capital Partners's IMVT Position: Q2 2026 in Review

GSA Capital Partners reduced its Immunovant (IMVT) stake by 10% in Q2 2026, selling an estimated $230K and leaving 65,267 shares worth $2.52M. The position accounts for 0.16% of the portfolio, ranked #93.

GSA Capital Partners first reported a position in IMVT in Q4 2020 and has held it in 13 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • GSA Capital Partners held 65,267 shares of Immunovant worth $2.52M as of Q2 2026.
  • GSA Capital Partners sold 7,553 Immunovant shares in Q2 2026, an estimated $230K.
  • Immunovant made up 0.16% of GSA Capital Partners's portfolio in Q2 2026, its #93 holding.
  • GSA Capital Partners first reported a position in Immunovant in Q4 2020 and has held it in 13 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.